Search results for "Liver Neoplasms."

showing 10 items of 733 documents

Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma

2017

Abstract Background Transarterial chemoembolisation is the standard of care for intermediate stage (BCLC B) hepatocellular carcinoma, but it is challenging to decide when to repeat or stop treatment. Here we performed the first external validation of the SNACOR (tumour Size and Number, baseline Alpha-fetoprotein, Child-Pugh and Objective radiological Response) risk prediction model. Methods A total of 1030 patients with hepatocellular carcinoma underwent transarterial chemoembolisation at our tertiary referral centre from January 2000 to December 2016. We determined the following variables that were needed to calculate the SNACOR at baseline: tumour size and number, alpha-fetoprotein level,…

AdultAged 80 and overMaleCarcinoma HepatocellularHepatocellular carcinomaLiver Neoplasms610 MedizinKaplan-Meier EstimateSNACORMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282Magnetic Resonance ImagingTreatment OutcomeTransarterial chemoembolisation610 Medical sciencesBiomarkers TumorHumansFemaleChemoembolization TherapeuticTomography X-Ray ComputedAgedNeoplasm StagingResearch Article
researchProduct

Cathepsin D, B and L circulating levels as prognostic markers of malignant progression

1996

Growing evidence indicates that lysosomal Cathepsins D (CD), B (CB) and L (CL) may promote carcinogenesis and tumor progression. Therefore, we evaluated their potential value as biochemical parameters of malignant progression in patients with benign diseases which may undergo malignant transformation, such as liver cirrhosis (LC) and chronic pancreatitis (CHP) as well as in hepatocellular carcinoma (HCC) and pancreatic cancer (DPC). CD, CB and CL serum levels were determined by immunoenzymatic assays in LC, CHP, HCC or DPC patients and correlated with a number of biochemical and clinical parameters of these diseases. CD serum levels were increased in LC, CHP and HCC, but not in the DPC grou…

AdultAged 80 and overMaleTumor progression.Carcinoma HepatocellularCirrhosiVHepatocellular carcinomaCathepsin LLiver NeoplasmsPancreatic cancerMiddle AgedPrognosisCathepsin DCathepsinsLCathepsin BPancreatic NeoplasmsCysteine EndopeptidasesChronic HepatiticEndopeptidasesBiomarkers TumorHumansFemaleAged
researchProduct

Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.

2002

<i>Objective:</i> This study was designed to determine the maximum tolerable dose (MTD) of gemcitabine plus docetaxel, both given on a weekly schedule, in patients with pretreated metastatic breast cancer (MBC). <i>Methods:</i> Heavily pretreated patients with MBC, aged 18–75 years with World Health Organization performance status of 0–2 were enrolled. Three escalating weekly doses of docetaxel (30, 35 and 40 mg/m<sup>2</sup>) followed by a weekly fixed dose of gemcitabine, 800 mg/m<sup>2</sup>, were administered on days 1, 8 and 15 of a 28-day cycle. Dose-limiting toxicity (DLT) included grade >3 hematologic toxicity and grade >2 stomat…

AdultCancer Researchmedicine.medical_specialtyLung NeoplasmsPaclitaxelmedicine.drug_classmedicine.medical_treatmentBone NeoplasmsBreast NeoplasmsDocetaxelWorld Health OrganizationAntimetaboliteGastroenterologyDeoxycytidineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisAgedChemotherapyPerformance statusDose-Response Relationship Drugbusiness.industryLiver NeoplasmsGeneral MedicineMiddle Agedmedicine.diseaseMetastatic breast cancerGemcitabineGemcitabineSurgeryRegimenTreatment OutcomeOncologyDocetaxelLymphatic MetastasisToxicityFemaleTaxoidsbusinessmedicine.drugOncology
researchProduct

Prognosis after surgery for multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors: Functionality matters

2021

Contains fulltext : 245221.pdf (Publisher’s version ) (Open Access) BACKGROUND: Metastasized pancreatic neuroendocrine tumors are the leading cause of death in patients with multiple endocrine neoplasia type 1. Aside from tumor size, prognostic factors of pancreatic neuroendocrine tumors are largely unknown. The present study aimed to assess whether the prognosis of patients with resected multiple endocrine neoplasia type 1-related nonfunctioning pancreatic neuroendocrine tumors differs from those with resected multiple endocrine neoplasia type 1-related insulinomas and assessed factors associated with prognosis. METHODS: Patients who underwent resection of a multiple endocrine neoplasia ty…

AdultDiagnostic ImagingMalemedicine.medical_specialtyAdolescentBiopsy030230 surgeryNeuroendocrine tumorsGastroenterologyArticleYoung Adult03 medical and health sciences0302 clinical medicineInternal medicineBiopsyTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]Multiple Endocrine Neoplasia Type 1medicineHumansMEN1Neoplasm MetastasisChildMultiple endocrine neoplasiaLymph nodeInsulinomaAgedNeoplasm StagingCause of deathAged 80 and overmedicine.diagnostic_testbusiness.industryLiver NeoplasmsHazard ratioDisease ManagementMiddle AgedPrognosismedicine.diseaseReconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]Pancreatic NeoplasmsPatient Outcome AssessmentNeuroendocrine Tumorsmedicine.anatomical_structure030220 oncology & carcinogenesisFemaleSurgeryDisease SusceptibilityNeoplasm GradingbusinessBiomarkers
researchProduct

Enhancement pattern of small hepatocellular carcinoma (HCC) at contrast-enhanced US (CEUS), MDCT, and MRI: intermodality agreement and comparison of …

2012

OBJECTIVE:To evaluate agreement between contrast-enhanced ultrasound (CEUS), multi-detector row computed tomography (MDCT) and magnetic resonance imaging (MRI) for the assessment of typical and atypical enhancement patterns of small hepatocellular carcinoma (HCC); and to compare diagnostic sensitivity of 2005 and 2010 American Association for the Study of Liver Diseases (AASLD) guidelines. MATERIALS AND METHODS: Between January 2008 and December 2009, we included cirrhotic patients with newly diagnosed 10-20 mm HCC imaged at two contrast-enhanced imaging techniques among CEUS, MDCT, and MRI. Dynamic studies were reviewed by two radiologists to assess enhancement pattern. Percentage of cases…

AdultDiagnostic ImagingMalemedicine.medical_specialtyCarcinoma HepatocellularContrast MediaEnhancement patternSensitivity and SpecificityImaging modalitiesTumor enhancementMcNemar's testmedicineHumansRadiology Nuclear Medicine and imagingAgedAged 80 and overmedicine.diagnostic_testbusiness.industryLiver NeoplasmsUltrasoundReproducibility of ResultsMagnetic resonance imagingGeneral MedicineMiddle Agedmedicine.diseaseUnited Statessmall hepatocellular carcinomaItalyHepatocellular carcinomaPractice Guidelines as TopicFemaleRadiologybusinesscontrast-enhanced ultrasoundContrast-enhanced ultrasound
researchProduct

Imaging findings of liver resection using a bipolar radiofrequency electrosurgical device—Initial observations

2010

Abstract Objective To assess contrast-enhanced US (CEUS), computed tomography (CT) and magnetic resonance (MR) imaging findings and serial changes of the treated area at follow-up in patients who underwent liver resection using a bipolar radiofrequency electrosurgical device. Methods Imaging findings of 27 patients with resected hepatocellular carcinomas (HCCs) ( n  = 24) and metastases ( n  = 3) (mean size: 2.6 cm), were retrospectively evaluated. Two readers assessed: the (a) presence, (b) thickness, (c) shape and (d) echogenicity (CEUS)/attenuation (CT)/signal intensity (MR imaging) at coagulated site and the (e) presence of residual tumor of the bipolar radiofrequency electrosurgical de…

AdultDiagnostic ImagingMalemedicine.medical_specialtyCarcinoma HepatocellularRadiofrequency ablationElectrosurgeryPilot ProjectsHepatocellular carcinoma Liver metastases Liver resection Radiofrequency ablation Coagulative necrosislaw.inventionlawmedicineHepatectomyHumansRadiology Nuclear Medicine and imagingAgedmedicine.diagnostic_testbusiness.industryLiver NeoplasmsEchogenicityMagnetic resonance imagingEquipment DesignGeneral MedicineMiddle Agedmedicine.diseasePeripheralEquipment Failure AnalysisTreatment OutcomeCoagulative necrosisHepatocellular carcinomaCatheter AblationResection marginELECTROSURGICAL DEVICEFemaleRadiologybusinessEuropean Journal of Radiology
researchProduct

Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma.

2010

Abstract Background Which is the least expensive recall policy for nodules in the cirrhotic liver remains unclear. Aim Aim of the study was to analyze the costs of different recall diagnostic strategies of hepatocellular carcinoma (HCC) on cirrhosis on a real series of patients. Methods 75 consecutive small liver nodules (10–30 mm) detected at conventional ultrasonography in 60 patients with cirrhosis were submitted to contrast-enhanced ultrasound, computed tomography and gadolinium-magnetic resonance imaging with a final diagnosis established according to the latest guidelines which include different strategies for nodules 10–19 mm or ≥20 mm. The actual costs required to fully characterise…

AdultDiagnostic ImagingMalemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularCost effectivenessHCC diagnosismedicineHumansProspective StudiesAgedAged 80 and overHepatologyRecallbusiness.industryNon invasiveUltrasoundLiver NeoplasmsGastroenterologyNodule (medicine)Middle Agedmedicine.diseaseHepatocellular carcinomaCost analysisCosts and Cost AnalysisFemaleRadiologymedicine.symptombusiness
researchProduct

Evolution of indeterminate hepatocellular nodules at Gd-EOB-DPTA-enhanced MRI in cirrhotic patients

2018

To retrospectively analyze the evolution of indeterminate hepatocellular nodules in cirrhotic patients on serial Gd-EOB-DPTA-enhanced MRI, and to identify predictors of HCC development. This IRB approved study included 33 cirrhotic patients with 69 indeterminate hepatocellular nodules (mean diameter 1.1 cm) at baseline Gd-EOB-DPTA-enhanced MRI and a Gd-EOB-DPTA-enhanced-MRI follow-up of at least 2 years. Two radiologists evaluated size and signal intensity of each nodule at baseline and follow-up. Age, cirrhosis etiology, and HCC history were recorded. Data were compared between nodules that became HCCs at follow-up (HCC) and those that did not (no-HCC). On follow-up, 5/69 nodules became HC…

AdultGadolinium DTPALiver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularContrast MediaCirrhosis; Gd-EOB-DTPA; HCC; Indeterminate hepatocellular nodule; Liver MRIGastroenterology030218 nuclear medicine & medical imagingLiver MRI03 medical and health sciences0302 clinical medicinePredictive Value of TestsInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingHCCneoplasmsNeuroradiologyAgedRetrospective StudiesAged 80 and overCirrhosimedicine.diagnostic_testbusiness.industryLiver NeoplasmsIndeterminate hepatocellular noduleNodule (medicine)Magnetic resonance imagingGeneral MedicineHCCSMiddle Agedmedicine.diseaseMagnetic Resonance Imagingdigestive system diseasesGd-EOB-DTPA030220 oncology & carcinogenesisPredictive value of testsEtiologyFemalemedicine.symptomIndeterminatebusiness
researchProduct

Focal nodular hyperplasia: a weight-based, intraindividual comparison of gadobenate dimeglumine and gadoxetate disodium-enhanced MRI

2019

PURPOSE: We aimed to qualitatively and quantitatively compare the enhancement pattern of focal nodular hyperplasia after gadobenate dimeglumine and gadoxetate disodium injection in the same patient. METHODS: 1.5 T magnetic resonance imaging (MRI) examinations of 16 patients with 21 focal nodular hyperplasias studied after the injection of both contrast media were evaluated. Both MRI studies were performed in all patients. A qualitative analysis was performed evaluating each lesion in all phases. For quantitative analysis we calculated signal intensity ratio, lesion-to-liver contrast ratio and liver parenchyma signal intensity gain on hepatobiliary phase. Statistical analysis was performed w…

AdultGadolinium DTPAMaleContrast MediaLiver MRI neoplasm030218 nuclear medicine & medical imagingGadoxetate DisodiumLesion03 medical and health sciences0302 clinical medicineMcNemar's testMegluminemedicineOrganometallic CompoundsHumansRadiology Nuclear Medicine and imagingIntraindividual comparisonAbdominal ImagingGADOBENATE DIMEGLUMINERetrospective Studiesmedicine.diagnostic_testbusiness.industryLiver NeoplasmsFocal nodular hyperplasiaMagnetic resonance imagingMiddle Agedmedicine.diseaseImage EnhancementMagnetic Resonance ImagingLiverEvaluation Studies as TopicFocal Nodular HyperplasiaFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessNuclear medicineSettore MED/36 - Diagnostica Per Immagini E RadioterapiaWeight based dosing
researchProduct

Value of texture analysis on gadoxetic acid–enhanced MRI for differentiating hepatocellular adenoma from focal nodular hyperplasia

2019

OBJECTIVE. The objective of our study was to assess the diagnostic performance of texture analysis (TA) on gadoxetic acid-enhanced MR images for differentiation of hepatocellular adenoma (HCA) from focal nodular hyperplasia (FNH).MATERIALS AND METHODS. This study included 40 patients (39 women and one man) with 51 HCAs and 28 patients (27 women and one man) with 32 FNH lesions. All lesions were histologically proven with preoperative MRI performed with gadoxetic acid. Two readers reviewed all the imaging sequences to assess the qualitative MRI characteristics. The T2-weighted fast spin-echo, hepatic arterial phase (HAP), and hepatobiliary phase (HBP) sequences were used for TA. Textural fea…

AdultGadolinium DTPAMaleGadoxetic acidCarcinoma Hepatocellulargenetic structuresAdolescenthepatocellular adenomaContrast MediaSensitivity and Specificity030218 nuclear medicine & medical imagingAdenoma Liver CellDiagnosis Differential03 medical and health sciences0302 clinical medicineImage Interpretation Computer-AssistedmedicineHumansRadiology Nuclear Medicine and imagingTexture (crystalline)Agedfocal nodular hyperplasiabusiness.industryLiver NeoplasmsFocal nodular hyperplasiatexture analysiGeneral MedicineHepatocellular adenomaMiddle Agedmedicine.diseaseImage EnhancementMagnetic Resonance Imagingdigestive system diseases030220 oncology & carcinogenesisFemaleMr imagesNuclear medicinebusinessSettore MED/36 - Diagnostica Per Immagini E RadioterapiaValue (mathematics)medicine.drugMRI
researchProduct